SymBio Pharmaceuticals Limited revised earnings guidance for the fiscal year ending December 31, 2023. For the period, the company revised net sales to JPY 6,477 million from JPY 7,000 million, operating loss to JPY 331 million from JPY 331 million, loss attributable to owners of parent to JPY 370 million from JPY 370 million and loss per share to JPY 9.34 from JPY 9.48.